Results 21 to 30 of about 39,529 (215)

Dose-dependent neuroprotective effect of enoxaparin on cold-induced traumatic brain injury

Neural Regeneration Research, 2017
Recent evidence exists that enoxaparin can reduce brain injury because of its anticoagulant activity. To investigate the potential therapeutic effect of enoxaparin on cold-induced traumatic brain injury, at 20 minutes after modeling, male BALB/c mouse ...
Ilknur Keskin, M Yalcin Gunal, Nilufer Ayturk, Ulkan Kilic, Mehmet Ozansoy, Ertugrul Kilic   +5 more
doaj   +1 more source

Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD [PDF]

, 2018
Background Enoxaparin may be used to prevent central venous catheter-related thrombosis in patients with CHD. We aimed to determine whether current enoxaparin dosing regimens effectively achieve anti-factor Xa concentrations within prophylactic goal ...
Israel, Emily N., Mastropietro, Christopher W., Thomas, Christopher A.   +2 more
core   +1 more source

Venous Thromboembolism Prophylaxis with Enoxaparin Versus Unfractionated Heparin in Patients with Low Body Weight

Plasmatology, 2023
Background Although reduced doses of enoxaparin have been studied in low body weight patients, no study has directly compared enoxaparin to unfractionated heparin for venous thromboembolism (VTE) prophylaxis in this population. Objective To determine the
David Michael Kaylor PharmD, Regan Merrell Wade PharmD, BCPS, Kathryn Brinkley Chappell PharmD, BCPS, Meredith Huff Niemann PharmD, BCPS, Vanessa Marie VanArsdale PharmD, BCPS   +4 more
doaj   +1 more source

Electronic risk assessment for venous thromboembolism: investigating physicians' rationale for bypassing clinical decision support recommendations. [PDF]

, 2014
Objective: The underutilisation of venous thromboembolism (VTE) prophylaxis is still a problem in the UK despite the emergence of national guidelines and incentives to increase the number of patients undergoing VTE risk assessments.
Brooks, Hannah, Coleman, Jamie J., McFarland, Lorraine, Nwulu, Ugochi, Richardson, Suzanna   +4 more
core   +3 more sources

Efficacy, Safety, and Timing of Anticoagulant Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients With Acute Spinal Cord Injury: A Systematic Review [PDF]

, 2017
Study Design: Systematic review. Objectives: The objective of this study was to answer 5 key questions: What is the comparative effectiveness and safety of (1a) anticoagulant thromboprophylaxis compared to no prophylaxis, placebo, or another ...
Arnold, Paul M., Casha, Steve, Fehlings, Michael G., Harrop, James S., Holmer, Haley K., Kwon, Brain K., Merli, Geno J., Norvell, Daniel C., Palmieri, Katherine, Tetreault, Lindsay G., Wilson, Jefferson R.   +10 more
core   +2 more sources

Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. [PDF]

, 2018
It is common knowledge that cancer patients are more prone to develop venous thromboembolic complications (VTE). It is therefore not surprising that patients with hepatocellular carcinoma (HCC) present with a significant risk of VTE, with the portal vein
Burra, P, Campello, E, Russo, Fp., Simioni, P, Spiezia, L, Zanetto, A   +5 more
core   +1 more source

Pharmacist recommendations for prophylactic enoxaparin monitoring and dose adjustment in trauma patients admitted to a surgical intensive care unit

Pharmacy Practice, 2019
Background: There is limited information describing pharmacist participation in prophylactic enoxaparin monitoring in the surgical intensive care unit (SICU).
Scrimenti A, Seabury RW, Miller CD, Ruangvoravat L, Darko W, Probst LA, Cwikla GM   +6 more
doaj   +1 more source

Bivalirudin started during emergency transport for primary PCI. [PDF]

, 2013
BACKGROUND: Bivalirudin, as compared with heparin and glycoprotein IIb/IIIa inhibitors, has been shown to reduce rates of bleeding and death in patients undergoing primary percutaneous coronary intervention (PCI).
Berg, J. van den, Bernstein, D., Clayton, T., Clemmensen, P., Coste, P., Deliargyris, E.N., Eggink, G.J., et al., Goldstein, P., Grunsven, P. van, Hamm, C.W., Hamon, M., Hof, A. van't, Huber, K., Lapostolle, F., Nef, H., Nibbe, L., Orto, M. Campo dell', Pocock, S., Prats, J., Schuette, D., Soulat, L., Steg, P.G., Steinmetz, J., Verheugt, F.W.A., Zeymer, U.   +25 more
core   +1 more source

Therapeutic Potential of Enoxaparin in Lichen Planus: Exploring Reasons for Inconsistent Reports

Frontiers in Pharmacology, 2018
Lichen planus (LP) is an uncommon mucocutaneous inflammatory condition, that is immunologically mediated, typically pruritic and often recurs. The currently advocated therapies are either not highly effective or associated with severe side effects ...
Rahul P. Patel, Madhur D. Shastri, Long Chiau Ming, Long Chiau Ming, Long Chiau Ming, Syed Tabish R. Zaidi, Gregory M. Peterson   +6 more
doaj   +1 more source

Application of thromboelastography in comparing coagulation difference of rivaroxaban and enoxaparin for thromboprophylaxis after total hip arthroplasty

Journal of Orthopaedic Surgery, 2021
Purpose: The purpose of this study was to compare the coagulation difference in patients with either rivaroxaban or enoxaparin as thromboprophylaxis after total hip arthroplasty (THA) regarding thromboelastography (TEG) and routine coagulation tests ...
Chao-wen Bai, Ru-xin Ruan, Sheng Pan, Chao-ran Huang, Xing-chen Zhang, Yong Pang, Xin Zheng, Kai-jin Guo   +7 more
doaj   +1 more source